Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and ...

Firefly Neuroscience, Inc. has announced two significant studies supporting its BNA™ platform, which uses advanced EEG technology to enhance drug efficacy evaluations and cognitive assessments ...

Firefly Neuroscience (AIFF) highlights two impactful studies that demonstrate the utility of advanced Resting Electroencephalograms and ...

Firefly Neuroscience, Inc. (NASDAQ:AIFF – Get Free Report) traded down 3.9% during mid-day trading on Tuesday . The stock traded as low as $3.43 and last traded at $3.70. 523,068 shares changed hands ...

Firefly Neuroscience, Inc. has announced progress in research using its FDA-cleared Brain Network Analytics (BNA™) technology to estimate patients' brain age, which could help assess the risk of ...

Firefly Neuroscience (AIFF) announced the advancement of research to assess a patient’s brain age, an estimation of the biological age of a person’s brain, via its FDA-cleared BNA technology ...

Get Wall Street's Hottest Chart Every Morning Firefly Neuroscience, Inc. AIFF shares are trading higher on Tuesday after the company announced the advancement of research to assess a patient’s ...

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological ...

Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change, driving innovation in brain health ...

KENMORE, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI ...